In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spine's Next Generation

Executive Summary

As the growth of the spine market outpaces virtually every other orthopedic segment, spine companies are hot. But the challenges that small spine start-ups face aren't only technological; they're also competitive as the market is defined by large spine players and a host of major orthopedic companies looking to tap into spine's potential.

You may also be interested in...



NuVasive: Outpacing a Slowing Spine Market

For the past several years, NuVasive has been growing faster than its rivals in spine, thanks to its innovative XLIF procedure, a lateral approach to minimally-invasive spine surgery. But now the spine market overall has hit a wall. In a market no longer growing, can NuVasive continue to grow?

Spinal Devices: Looking for a Twist Rather than a Tweak

Medical device investors still see great potential in companies developing products to treat the spine. But they're particularly eager to find companies with fresh new approaches toward treatments rather than those that offer a marginal improvement to current products on the market.

Spine Update: BMP Use Continues to Expand

Medtronic recently declared that InFUSE, the company's blockbuster spine bone graft product that provides the growth factor rhBMP-2 as part of a lumbar fusion cage, was well on its way to becoming standard of care in spine surgery. The company's success has fueled interest in a plethora of potential entrants into the biologic bone formation market.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL082593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel